Amiodarone: Nursing Drug Guide, Pulmonary Toxicity & QT Monitoring
Reserved for life-threatening ventricular arrhythmias, amiodarone carries boxed-level warnings for pulmonary, hepatic, and cardiac toxicity—including QT prolongation and torsade de pointes—while IV therapy adds hypotension risk when infusion rates or cumulative daily doses are wrong.
Prescribing information reserves amiodarone for life-threatening recurrent ventricular fibrillation (VF) and hemodynamically unstable ventricular tachycardia (VT) when other therapies fail. Toxicities can be fatal: pulmonary injury (including acute-onset infiltrates and ARDS with IV use), hepatotoxicity, thyroid dysfunction, and proarrhythmia with QTc prolongation and torsade de pointes. IV therapy requires timed infusion rates, in-line filter, central line when possible, and continuous monitoring—mean daily IV doses above 2100 mg increased hypotension risk in trials.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Obtain baseline chest imaging, pulmonary function tests, thyroid studies, and hepatic panel before therapy; correct potassium, magnesium, and calcium first. For IV loads, never bolus—follow product-specific timed rates with filter and hemodynamic monitoring. Teach patients to report new cough, dyspnea, jaundice, or palpitations, and schedule pulmonary and liver surveillance every 3–6 months on chronic oral therapy.
Most common brand names
Amiodarone is available as generic tablets and injection and under several trade names depending on country and formulation.
Common U.S. names: Cordarone, Pacerone (oral tablets); Nexterone (IV premixed injection). Verify vial concentration and infusion table—premixed bags differ from pharmacy-compounded drips.
Why we give it — Indications
Amiodarone is reserved for documented, life-threatening ventricular arrhythmias when safer alternatives are inadequate. Labeling emphasizes using alternative agents first because toxicity can be fatal.
| Use | Detail |
|---|---|
| IV (Nexterone) | Initiation and prophylaxis of frequently recurring VF and hemodynamically unstable VT refractory to other therapy |
| Oral tablets | Treatment of documented life-threatening recurrent VF and life-threatening recurrent hemodynamically unstable VT when other agents fail or cannot be tolerated |
| Not routine for | Stable atrial fibrillation rate control alone—use only when prescriber documents life-threatening ventricular indication per labeling intent |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Amiodarone is a primarily class III antiarrhythmic that prolongs cardiac repolarization and refractory period. It also blocks sodium, potassium, and calcium channels and has noncompetitive alpha- and beta-adrenergic blocking activity. High iodine content affects thyroid hormone metabolism. The drug has a very long half-life and persists in tissue for weeks to months after discontinuation—adverse effects and interactions can linger.
Dosing overview
Institutional protocols and product formulations may vary. Always verify the specific product label and pharmacy preparation.
IV (Nexterone premixed injection — Table 1 labeling)
| Phase | Dose | Administration rate (labeling) |
|---|---|---|
| Loading — first rapid | 150 mg over first 10 min (15 mg/min) | Infuse 150 mg/100 mL (1.5 mg/mL) at 10 mL/min |
| Loading — slow | 360 mg over next 6 h (1 mg/min) | 360 mg/200 mL (1.8 mg/mL) at 0.556 mL/min |
| Loading — remainder | 540 mg over remaining 18 h (0.5 mg/min) | Decrease rate to 0.278 mL/min |
| Maintenance (after 24 h) | 720 mg per 24 h (0.5 mg/min) | 360 mg/200 mL at 0.278 mL/min |
| Breakthrough VF/VT | 150 mg supplemental infusion | Over 10 min (10 mL/min for 150 mg/100 mL bag) |
On a small screen, swipe or scroll sideways to see the full table.
Oral tablets (labeling)
Renal impairment: Not specified in the reviewed prescribing information for dose adjustment (drug not primarily renally eliminated).
Hepatic impairment: Use with caution; hepatotoxicity can be fatal—monitor transaminases closely. Not specified in the reviewed prescribing information for numeric dose reduction.
Missed oral dose: Not specified in the reviewed prescribing information. Do not double doses; contact prescriber/pharmacist for guidance on chronic therapy.
Before you give it — Safety check
Pretreatment checks
- Confirm life-threatening VF/VT indication documented; review rhythm strips and ECG
- Baseline chest X-ray, pulmonary-function tests (including diffusion capacity), thyroid function tests, and liver function tests per labeling
- Review basic metabolic panel—correct hypokalemia, hypomagnesemia, and hypocalcemia before starting (exaggerates QTc prolongation)
- Perform medication reconciliation for interacting antiarrhythmics, digoxin, warfarin, QT-prolonging drugs, and iodine exposure
Contraindications
- Cardiogenic shock
- Sick sinus syndrome, second- or third-degree AV block, or bradycardia leading to syncope without a functioning pacemaker
- Known hypersensitivity to amiodarone or any component, including iodine
Important interactions
| Drug / class | Effect | Nursing action |
|---|---|---|
| Other QT-prolonging antiarrhythmics | Increased torsade de pointes risk | Reserve combination only for life-threatening VT/VF per labeling; continuous QTc monitoring |
| Digoxin | Increased digoxin levels | Monitor digoxin level and signs of toxicity; expect lower maintenance digoxin dose per prescriber |
| Warfarin | Potentiates anticoagulant effect | More frequent INR monitoring when combined; bleeding education |
| CYP inhibitors / inducers (e.g., certain macrolides, azoles) | Altered amiodarone concentrations | Pharmacist interaction review before new antimicrobials or antifungals |
On a small screen, swipe or scroll sideways to see the full table.
Administration
IV: Administer whenever possible through a central venous catheter dedicated to amiodarone. Use an in-line filter. Program pump rates to match the product infusion table—do not administer IV push or bolus. Monitor blood pressure and rhythm continuously; mean daily doses above 2100 mg were associated with increased hypotension in controlled trials.
- Verify bag concentration (e.g., 1.5 mg/mL or 1.8 mg/mL premixed) and phase of 24-hour loading protocol before starting
- Double-check pump rate in mL/hr with pharmacy for each phase transition (10 min, 6 h, 18 h segments)
- Oral: administer consistently with regard to meals; divide daily doses with meals when total daily dose is 1000 mg or higher or if GI intolerance occurs
Treating Nexterone like a routine IV piggyback without timed rates, filter, and hemodynamic monitoring is a preventable high-risk error. Follow high-alert medication administration and IV infusion pump setup verification steps.
Expected therapeutic response
- Termination or reduced frequency of life-threatening VF/VT episodes on telemetry
- Hemodynamic stability during IV loading (BP and perfusion maintained)
- Oral therapy: improved rhythm control over days to weeks—full effect delayed because of long half-life
Red flags — Stop and act
Escalate immediately for organ toxicity, proarrhythmia, or hemodynamic collapse.
- New or worsening cough, exertional dyspnea, fever, or hypoxia—possible pulmonary toxicity (including acute-onset injury days to weeks after IV)
- Jaundice, dark urine, RUQ pain, or transaminases >3× normal (or doubling from elevated baseline)—hold and evaluate hepatotoxicity
- QTc ≥500 ms, polymorphic VT, or torsade de pointes—stop drug, magnesium/pacing per protocol, notify prescriber
- Symptomatic hypotension, cardiogenic shock, or bradycardia during IV infusion—slow or stop infusion per protocol; vasopressors/pacing as ordered
- Thyroid storm or severe hypothyroid symptoms—urgent thyroid studies and prescriber/endocrine consult
Adverse effects
| Adverse effect | Notes (labeling) | Nursing response |
|---|---|---|
| Pulmonary toxicity | Hypersensitivity pneumonitis or interstitial/alveolar pneumonitis; clinically manifest disease up to ~17% in some series; fatal ~10% of pulmonary toxicity cases; IV acute-onset injury reported | Baseline and periodic chest X-ray/PFTs; stop for new respiratory symptoms; oxygen and escalation per protocol |
| Hepatotoxicity | Can be fatal; discontinue for clinical liver injury | Baseline and periodic AST/ALT; hold when >3× ULN or doubling from elevated baseline |
| Bradycardia / AV block | Common with IV and oral therapy | Telemetry; pacemaker readiness; hold per Hold Rule |
| Hypotension (IV) | Dose-related; higher risk when mean daily IV dose >2100 mg | Continuous BP; slow/stop infusion; notify prescriber |
| QT prolongation / TdP | Proarrhythmia; TdP associated with QTc ≥500 ms | Correct electrolytes; continuous telemetry and QTc documentation; avoid additional QT-prolonging drugs |
| Thyroid dysfunction | Hypothyroidism up to ~10%; hyperthyroidism ~2% (oral labeling) | Baseline and periodic TSH; assess for weight change, heat/cold intolerance |
| Photosensitivity / blue-gray skin | Photosensitivity ~10%; skin discoloration with sun exposure | Sun protection, protective clothing; document skin changes |
| Corneal microdeposits | Common; usually reversible | Vision changes—ophthalmology referral per prescriber |
On a small screen, swipe or scroll sideways to see the full table.
Overdose, toxicity, and antidote
Fatal overdoses have occurred. Effects of inadvertent IV overdose per Nexterone labeling include hypotension, cardiogenic shock, bradycardia, AV block, and hepatotoxicity.
Management (labeling)
- Hypotension / cardiogenic shock: slow infusion rate and/or standard therapy (vasopressors, inotropes, volume expansion) per protocol
- Bradycardia / AV block: temporary pacing per protocol
- Hepatotoxicity: monitor hepatic enzymes closely; supportive care
Antidote: Not specified in the reviewed prescribing information—no specific reversal agent. Neither amiodarone nor desethylamiodarone (DEA) is dialyzable.
Contact local poison control or medical toxicology services for overdose guidance per facility protocol and local emergency guidance.
Look-alike / sound-alike and error prevention
- Amiodarone vs amitriptyline—sound-alike; verify medication name and indication (antiarrhythmic vs antidepressant)
- IV push vs timed infusion—amiodarone must never be given as a bolus; use only labeled infusion durations
- Premixed bag concentration—150 mg/100 mL vs 360 mg/200 mL require different mL/min rates
- Oral loading vs maintenance—800–1600 mg/day loading can be confused with 400 mg maintenance
- Digoxin dose—automatic digoxin dose reduction may be needed when amiodarone starts—pharmacy should reconcile
High-risk populations
| Population | Considerations |
|---|---|
| Older adults | Higher risk of bradycardia, AV block, hypotension, and thyroid dysfunction—enhanced monitoring |
| Thyroid disease / nodules | Monitor thyroid function closely; hyper- or hypothyroidism can occur |
| Pre-existing lung disease | Increased pulmonary toxicity risk—low threshold to stop for new symptoms |
| Pregnancy | May cause fetal harm; neonatal bradycardia, thyroid abnormalities, growth restriction reported—use only if clearly needed |
| Lactation | Breastfeeding not recommended (labeling); LactMed advises against breastfeeding during therapy and for months after stop because of slow elimination and iodine in milk |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Cardiac rhythm, QTc (especially during IV infusion), blood pressure, and perfusion
- Pulmonary status, chest X-ray, and PFTs—including diffusion capacity at baseline and every 3–6 months on chronic oral therapy
- AST, ALT, alkaline phosphatase at baseline and periodically
- TSH and clinical thyroid symptoms; consider additional thyroid tests if dysfunction suspected
- Visual symptoms; corneal deposits are common
- INR and bleeding if patient receives warfarin; digoxin level if on digoxin
Document
- Indication for life-threatening arrhythmia, baseline studies completed, and electrolytes corrected
- IV: product, phase, pump rate (mL/hr), filter used, blood pressure trends, and breakthrough bolus doses
- Patient education on pulmonary symptoms, sun protection, and when to seek urgent care
Patient teaching
- Report new or worsening shortness of breath, cough, fever, chest pain, yellowing of skin or eyes, dark urine, or persistent nausea
- Use high-SPF sunscreen and protective clothing—photosensitivity is common; blue-gray skin discoloration may occur on long-term therapy
- Do not stop or change dose without prescriber guidance—sudden discontinuation can worsen heart arrhythmia risk
- Keep all laboratory and imaging appointments for lung, liver, and thyroid monitoring
- Tell every clinician you take amiodarone before new medicines—especially antibiotics, antifungals, and other heart drugs
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Cardiogenic shock, sick sinus syndrome, second- or third-degree AV block, or symptomatic bradycardia without pacemaker
- Known hypersensitivity or iodine allergy to drug components
- New pulmonary symptoms, suspected infiltrates, or clinical respiratory deterioration
- Transaminases >3× ULN, doubling from elevated baseline, or signs of clinical liver injury
- QTc ≥500 ms, torsade de pointes, or symptomatic proarrhythmia
- Symptomatic hypotension during IV therapy or IV order incompatible with labeled infusion durations/filter
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Phase transitions | Post checklist at 10 min, 6 h, and 18 h to change pump rate—wrong phase rate causes hypotension |
| Dedicated line | Use central line reserved for amiodarone when possible; document in-line filter change per policy |
| Electrolytes | Recheck potassium and magnesium before IV load and with diuretic therapy—trend potassium per protocol |
| Oral consistency | Take with meals the same way each day—food affects absorption |
| Drug persistence | Adverse effects and interactions can persist weeks after stop—document discontinued date in handoff |
| Ask pharmacy when | Bag concentration changes, interaction with new QT-prolonging drug, or transition from IV to oral dosing |
On a small screen, swipe or scroll sideways to see the full table.
Clinical practice integration and workflow
Amiodarone therapy is a longitudinal safety program—not a single dose. Nurses bridge emergency IV loading, oral conversion, and months of surveillance for lung, liver, and thyroid injury.
1. Check-before-you-give protocol
- Right patient, drug, dose, route, and documented VF/VT indication
- Baseline chest imaging, PFTs, thyroid tests, LFTs on file—or obtained before first dose when feasible
- Potassium, magnesium, and calcium reviewed and repleted per prescriber
- IV: filter, central access, pump program verified independently by second nurse
2. High-alert and safety badge
High-alert antiarrhythmic — organ toxicity and IV rate riskMany facilities classify amiodarone as high-alert because of pulmonary/hepatic/cardiac warnings, IV infusion complexity, and prolonged drug persistence after discontinuation.
3. Clinical workflow: hold and question rules
- Any new cough or O2 desaturation on therapy triggers hold and prescriber notification—even early in IV course
- Rising AST/ALT or clinical jaundice: hold and repeat hepatic panel same day
- QTc at or above 500 ms: hold and obtain magnesium/potassium; prescriber and pharmacy review
4. Critical teach-back questions
- “What breathing changes should you report immediately?” (New cough, worsening shortness of breath, fever.)
- “Why must you attend lung and blood test appointments even if you feel well?” (Toxicity can be silent until advanced.)
5. Care coordination
Cardiology / electrophysiology: Rhythm control plan, transition IV→oral, device/pacing needs, repeat-dose antiarrhythmic decisions
Pharmacist: Interaction review (digoxin, warfarin, QT drugs), IV phase rates, and therapeutic drug monitoring coordination
🧠 Quick mental checklist
- Is this truly life-threatening VF/VT—and are alternatives documented?
- Are baseline lung, liver, thyroid, and electrolyte checks complete?
- IV: correct phase, rate, filter, and BP monitoring—not a bolus?
- Any new cough, jaundice, or QTc at or above 500 ms?
- Oral: consistent meals and 3–6 month surveillance scheduled?
Amiodarone NCLEX practice questions
Practice NCLEX-style clinical judgment practice for amiodarone with a tabbed ICU case (MAR, labs, vitals, nursing notes), then priority action, pulmonary-toxicity cue recognition, electrolyte/QT trend interpretation, matrix urgency sorting, hold-rule judgment, and IV-phase cloze—recognise cues → analyse → prioritise → act → evaluate outcomes (symptom surveillance vs proarrhythmia vs infusion safety).
Select a tab to view MAR, labs, vitals, and nursing note details for this case.
- Nexterone (amiodarone) IV loading per protocol — phase 2: 360 mg/200 mL running 0.556 mL/min (started 0800)
- Amiodarone 200 mg PO BID scheduled — held today pending prescriber review
- Furosemide 40 mg IV daily — given 0700
- Digoxin 0.125 mg PO daily — last given yesterday
- Admission baseline: chest X-ray clear; PFTs WNL; TSH 2.1 mIU/L; AST 28 U/L, ALT 32 U/L
- Today 1000: K+ 3.2 mEq/L (was 3.9); Mg2+ 1.6 mg/dL; AST 48 U/L, ALT 52 U/L
- Telemetry QTc 512 ms (was 468 ms pre-load); rhythm sinus 62/min
- 1015: BP 92/58 (baseline 110/70), HR 62, RR 22, SpO2 91% on 2 L NC (was 96% earlier)
- Temp 37.4 °C; patient reports new dry cough ×2 days
- 0900: In-line filter verified; dedicated central line; pump rate double-checked with pharmacy
- 1005: Patient reports increased shortness of breath with exertion; fine crackles at bases new
- 1010: BP trending down during phase 2 infusion—RN reviewing labs and vitals tabs before next action
Answer key & rationale
Frequently asked questions
What baseline tests should nurses verify before starting amiodarone?
Obtain baseline chest X-ray, pulmonary-function tests including diffusion capacity, thyroid function tests, and liver aminotransferases. Correct hypokalemia, hypomagnesemia, and hypocalcemia before therapy because electrolyte disorders worsen QTc prolongation and torsade de pointes risk.
When should a nurse hold amiodarone?
Hold for shock, high-grade heart block or symptomatic bradycardia without pacemaker, hypersensitivity, new pulmonary toxicity signs, clinical liver injury or marked transaminase rise, QTc ≥500 ms or torsade de pointes, symptomatic IV hypotension, or non-compliant IV infusion orders.
How fast should IV amiodarone be given?
Nexterone labeling requires phased infusions—for example 150 mg over the first 10 minutes, then slower rates over 6 and 18 hours—not IV push. Use in-line filter and central line when possible; monitor QTc and blood pressure.
Is there an antidote for amiodarone overdose?
No specific antidote is listed. Treat hypotension, shock, bradycardia, AV block, and hepatotoxicity supportively; pacing and slow infusion adjustment per labeling. Drug is not dialyzable.
Can patients breastfeed on amiodarone?
Tablet labeling recommends against breastfeeding. LactMed states breastfeeding is not recommended during therapy or for several months after discontinuation due to slow elimination and iodine excretion into milk.
References
- U.S. National Library of Medicine. NEXTERONE (amiodarone hydrochloride) injection — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e9108958-b8d7-4fba-87c3-9a32990de551
- U.S. National Library of Medicine. AMIODARONE HYDROCHLORIDE tablets — Full prescribing information. DailyMed (setid 0caedb97-56fd-4ec0-bfb2-c7683b8f5f1b).https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0caedb97-56fd-4ec0-bfb2-c7683b8f5f1b
- Drugs and Lactation Database (LactMed). Amiodarone. Bethesda (MD): National Institute of Child Health and Human Development.https://www.ncbi.nlm.nih.gov/books/NBK500560/
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.